|Bid||0.00 x 1000|
|Ask||18.25 x 900|
|Day's Range||17.31 - 18.62|
|52 Week Range||5.04 - 23.88|
|Beta (5Y Monthly)||0.88|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jun 25, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Oct 14, 1999|
|1y Target Est||10.17|
Rite Aid (RAD) is gaining from efforts to enhance customers' shopping in these trying times. Also, it is progressing well with the EnvisionRxOptions strategy.
Investors need to pay close attention to Rite Aid (RAD) stock based on the movements in the options market lately.
Morgan Stanley analyst Ricky Goldwasser reiterated an Equal Weight rating on the shares, while shaving $4 off her price target, to $45.
The U.S. Department of Health and Human Services said on Tuesday it would extend its partnership with private pharmacies and grocery chains to provide better access to COVID-19 testing. The partnership with CVS Health Corp, Rite Aid Corp , Walgreens boots Alliance Inc, Kroger and Walmart Inc has been scaled up to more than 600 COVID-19 testing sites across the country. The partnership has been extended at a time when drive-through coronavirus testing sites have been popping up across the country, and seeks to ramp up testing, reduce pressure on emergency rooms, while keeping patients in their cars to avoid spreading the infection.
Rite Aid customers can support the life-saving work of Children’s Miracle Network Hospitals during the company's Miracle Balloon Campaign.
As of late, it has definitely been a great time to be an investor of Rite Aid Corporation
Top Ranked Momentum Stocks to Buy for June 30th
Moody's Investors Service, ("Moody's") today assigned a Caa1 rating to Rite Aid Corporation's ("Rite Aid") new senior secured notes. "Rite Aid continues to address its 2023 maturities which is a credit positive but operational challenges remain", Moody's Vice President Mickey Chadha stated. "We expect only modest improvement in credit metrics and free cash flow in the next 12 months as the retail pharmacy space remains under pressure and new management initiatives will take longer to show results in the midst of the uncertain business environment", Chadha further stated.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]
Rite Aid's (RAD) Q1 results gain from increased prescription deliveries, as its stores remained open amid COVID-19. However, it withdraws the fiscal 2021 view due to uncertain COVID-19 impacts.
Shares of Rite Aid (NYSE: RAD) moved higher by 28.6% after the company reported Q1 results.Quarterly ResultsEarnings per share increased 71.43% year over year to ($0.04), which beat the estimate of ($0.38).Revenue ofView more earnings on RADShares of Rite Aid (NYSE:RAD) moved higher by 28.6% after the company reported Q1 results.Quarterly Results Earnings per share increased 71.43% year over year to ($0.04), which beat the estimate of ($0.38).Revenue of $6,027,000,000 up by 12.17% year over year, which beat the estimate of $5,610,000,000.Outlook Rite Aid hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.Technicals 52-week high: $23.88Company's 52-week low was at $5.04Price action over last quarter: Up 41.49%Company Overview Rite Aid Corp is a large retail drugstore chain in the United States. The company reports via two segments: retail pharmacy and pharmacy services. The retail pharmacy segment generates revenue primarily through the sale of prescription drugs, along with an assortment of merchandise that includes over-the-counter medications, health and beauty aids, personal-care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise and numerous other everyday consumables. The pharmacy-services segment relates to EnvisionRx, a fully owned subsidiary that operates as a pharmacy benefit management provider offering a broad range of pharmaceutical services.See more from Benzinga * Afternoon Market Stats in 5 Minutes * Morning Market Stats in 5 Minutes * 20 Healthcare Stocks Moving In Thursday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
(Bloomberg) -- Rite Aid Corp. is asking some of its creditors for a few more years of patience while it tries to turn around the struggling drugstore chain.Bondholders are being asked to swap $750 million of Rite Aid’s unsecured 2023 notes for securities that wouldn’t be paid back for three more years, according to a statement. They’d also have to accept a haircut on their holdings. In return, the new notes would be secured by Rite Aid’s assets and pay a higher interest rate.The debt swap was disclosed as part of a first-quarter earnings release that included a net loss from continuing operations of $72.7 million. Rite Aid withdrew its forecasts, citing effects of the coronavirus pandemic on its business.“Rite Aid’s fiscal 2021 is shaping up to be another challenging year, as it must face lingering structural challenges and pandemic-related shortfalls,” Bloomberg Intelligence analysts Jonathan Palmer and Fallon Stephan wrote in a note prior to the earnings results.Exchange TermsThe proposed swap would exchange the unsecured 2023 notes that pay interest of 6.125% for secured notes that come due in 2026 and pay 8%. Participating bondholders would receive $800 in new notes and $194 in cash for every $1,000 of face value if they tender early.Rite Aid, based in Camp Hill, Pennsylvania, is also asking bondholders for permission to create more secured debt.The drugstore chain has continued to struggle with high leverage tied to its $3.3 billion of debt amid pressure on its pharmacy and retail businesses.While its deal to sell about half of its stores to Walgreens helped reduce debt, Rite Aid has been trying to improve in-store retail sales while also dealing with falling pharmacy revenue due to reimbursement pressure, according to BI.New BossThe company recruited Heyward Donigan, a digital health executive with little retail background, to be its new chief executive and presented a vision for its turnaround in March.“Rite Aid emerged from its asset sale to Walgreens as a smaller competitor with a cleaner, but still highly levered, balance sheet. It faces an uphill climb due to structural conditions as it tries to improve profitability,” Bloomberg Intelligence said in a March note.It benefited from customers stocking up on essential medications and cleaning supplies in anticipation of the Coronavirus shelter-in-place orders, according to the earnings statement. However, many of Rite Aid’s stores are in states that have been hardest hit, according to BI, so the initial burst of purchases may not be sustained as the pandemic drags on.The notes targeted by Rite Aid rose by 3 cents on the dollar to 98 cents, according to Trace bond trading data. Some of its longer-dated unsecured debt hovers around 85 cents. The early tender deadline is July 9 at 5 p.m. New York time. The exchange offer expires July 23 at 11:59 p.m.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Rite Aid rallies more than 20% after a top- and bottom-line beat. Despite the move, the stock could have more upside from here.
(Bloomberg) -- Rite Aid Corp. withdrew its fiscal year 2021 forecast on Thursday, citing an uncertain economy and concerns about a slow return to doctor’s offices and surgeries hindering prescription demand.“There’s just such a wide range of outcomes here,” said Chief Financial Officer Matt Schroeder on a call discussing the company’s fiscal first-quarter results.Other risks cited included possible shortages in certain generic drugs, a membership drop in its pharmacy benefit manager, and even the added costs for cleaning during the pandemic. Still, Rite Aid shares surged 20% Thursday morning after the company posted better-than-expected results from the fiscal first quarter of 2021, which ended May 30.Chief Executive Officer Heyward Donigan said stimulus efforts will likely cushion the effects of an economic downturn. Still, she said, the company is considering how a long and deep economic contraction could affect its business.“It’s still a risk I think we all have to be aware of,” Donigan said.Possible opportunities for the company include higher demand than usual for flu shots this fall and continued expansion of its Covid-19 testing abilities. In the first three weeks of June, Rite Aid’s sales in the front of the store increased about 7%, excluding tobacco products.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Rite Aid (RAD) delivered earnings and revenue surprises of 92.59% and 7.66%, respectively, for the quarter ended May 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Rite Aid (NYSE:RAD) moved higher by 6.8% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share were up 71.43% over the past year to ($0.04), which beat the estimate of ($0.38).Revenue of $6,027,000,000 higher by 12.17% from the same period last year, which beat the estimate of $5,610,000,000.Outlook Rite Aid hasn't issued any earnings guidance for the time being.Rite Aid hasn't issued any revenue guidance for the time being.How To Listen To The Conference Call Date: Jun 25, 2020View more earnings on RADTime: 08:30 AMET Webcast URL: https://www.riteaid.com/corporate/investor-relations/presentationsTechnicals 52-week high: $23.88Company's 52-week low was at $5.04Price action over last quarter: Up 11.98%Company Overview Rite Aid Corp is a large retail drugstore chain in the United States. The company reports via two segments: retail pharmacy and pharmacy services. The retail pharmacy segment generates revenue primarily through the sale of prescription drugs, along with an assortment of merchandise that includes over-the-counter medications, health and beauty aids, personal-care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise and numerous other everyday consumables. The pharmacy-services segment relates to EnvisionRx, a fully owned subsidiary that operates as a pharmacy benefit management provider offering a broad range of pharmaceutical services.See more from Benzinga * Earnings Scheduled For June 25, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Shares of Rite Aid Corp. ran up 5.4% in premarket trading Thursday, after the drug store chain reported a narrower-than-expected fiscal first-quarter loss and revenue that rose more than forecast. The net loss for the quarter to May 30 narrowed to $63.54 million, or $1.19 a share, from a loss of $99.7 million, or $1.88 a share, in the year-ago period. Excluding non-recurring items, the adjusted loss per share was 4 cents, compared with the FactSet loss consensus of 38 cents. Revenue rose 12.2% to $6.03 billion, above the FactSet consensus of $5.61 billion. Retail pharmacy sales rose 6.6%, as front-end sales increased 14.2% and pharmacy sales grew 2.2%. Excluding cigarettes, front-end same-store sales increased 16.0%, amid strength in sales of cleaning products, sanitizers, wipes, paper products, liquor, over-the-counter products and summer seasonal items. The company said it has withdrawn its fiscal 2021 guidance issued in March, given the uncertainties about the potential impact of the COVID-19 pandemic. The stock has lost 11.1% over the past three months through Wednesday, while the S&P 500 has hiked up 23.2%.
Rite Aid Corporation (NYSE: RAD) ("Rite Aid" or the "Company") today announced that it has commenced an exchange offer (the "Exchange Offer") to Eligible Holders (as defined herein) for up to $750 million aggregate principal amount (the "Maximum Amount") of its outstanding 6.125% Senior Notes due 2023 (the "Old Notes") for newly issued 8.000% Senior Secured Notes due 2026 (the "New Notes") and cash, upon the terms and subject to the conditions set forth in the offering memorandum and consent solicitation statement dated June 25, 2020 (the "Offering Memorandum and Consent Solicitation Statement"). The purpose of the Exchange Offer is to improve the Company’s maturity profile by extending the maturity date of a portion of the Old Notes from April 2023 to November 2026. The Company is concurrently soliciting consents from all holders of the Old Notes (each, a "Holder") to adopt certain proposed amendments to the indenture governing the Old Notes for a separate cash consent payment. As detailed below, for each $1,000 principal amount of Old Notes tendered before the Early Deadline and accepted for exchange, Holders will receive Total Exchange Consideration of $800 of New Notes and $194 in cash; the effective result of this is that, for each $1,000 of such Old Notes, $800 will be exchanged for New Notes at par and $200 will be exchanged for cash at 97% of par.
NEW YORK, NY / ACCESSWIRE / June 25, 2020 / Rite Aid Corp. (NYSE:RAD) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on June 25, 2020 at 8:30 AM Eastern ...
Moody's Investors Service, ("Moody's") downgraded General Nutrition Centers, Inc. ("GNC") probability of default rating (PDR) to D-PD from Ca-PD following the company's announcement  that it has commenced voluntary prearranged Chapter 11 proceedings. "General Nutrition Centers needed to address its upcoming maturities which required essentially a full refinancing of its capital structure," said Moody's Vice President, Christina Boni.
GNC Holdings Inc, the vitamin and herbal supplement retailer, has filed for bankruptcy, with plans to close at least 800 to 1,200 locations and possibly sell itself. GNC had been trying to reduce its nearly $900 million debt load amid falling sales at its brick-and-mortar stores when the coronavirus pandemic forced thousands of locations to close temporarily, cutting off a major revenue source. The Pittsburgh-based company, whose name is an acronym for General Nutrition Centers, plans a "dual-path" restructuring where it would either be sold as a going concern, or improve its balance sheet by shedding more than $300 million of debt.